Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 3 (March)

1. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
   Nat Rev Cancer, 5(3): 172-83. [Abstract] [Full-text]
2. Label-free detection of small-molecule-protein interactions by using nanowire nanosensors.
   Proc Natl Acad Sci U S A, 102(9): 3208-12. [Abstract] [Full-text]
3. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
   Proc Natl Acad Sci U S A, 102(9): 3395-400. [Abstract] [Full-text]
4. Expression and amplification of therapeutic target genes in retinoblastoma.
   Graefes Arch Clin Exp Ophthalmol, 243(2): 156-62. [Abstract] [Full-text]
5. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
   Clin Cancer Res, 11(4): 1563-71. [Abstract] [Full-text]
6. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
   Blood, 105(6): 2281-6. [Abstract] [Full-text]
7. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
   Blood, 105(6): 2473-9. [Abstract] [Full-text]
8. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
   Cancer Res, 65(5): 1897-903. [Abstract] [Full-text]
9. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
   Bone Marrow Transplant, 35(6): 601-8. [Abstract] [Full-text]
10. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways.
    Clin Cancer Res, 11(5): 1928-40. [Abstract] [Full-text]
11. Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl.
    Leuk Res, 29(5): 565-72. [Abstract] [Full-text]
12. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Z Gastroenterol, 43(3): 267-73. [Abstract] [Full-text]
13. How to develop a successful cancer drug--molecules to medicines or targets to treatments?
    Eur J Cancer, 41(5): 676-82. [Abstract] [Full-text]
14. A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nat Biotechnol, 23(3): 329-36. [Abstract] [Full-text]
15. Imatinib and gastrointestinal stromal tumors: Where do we go from here?
    Mol Cancer Ther, 4(3): 495-501. [Abstract] [Full-text]
16. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
    ANZ J Surg, 75(3): 165-72. [Abstract] [Full-text]
17. c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage.
    J Biol Chem, 280(12): 11147-51. [Abstract] [Full-text]
18. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
    Biochem J, 387: 231-8. [Abstract] [Full-text]
19. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Arch Dermatol, 141(3): 368-70. [Abstract] [Full-text]
20. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
    Cancer Res, 65(6): 2047-53. [Abstract] [Full-text]
21. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.
    J Exp Med, 201(6): 925-35. [Abstract] [Full-text]
22. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
    Ann Oncol, 16(4): 566-78. [Abstract] [Full-text]
23. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Mol Pharmacol, 67(4): 1166-76. [Abstract] [Full-text]
24. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
    Blood, 105(7): 2640-53. [Abstract] [Full-text]
25. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
    Pediatr Blood Cancer, 44(5): 511-5. [Abstract] [Full-text]
26. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients.
    Eur J Radiol, 54(1): 118-23. [Abstract] [Full-text]
27. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.
    Oncogene, 24(14): 2317-29. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.